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indicate that the severity of atherosclerosis was greater with 
aortic aneurysm or may reflect a difference in pathogenesis. 
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Regarding "Evaluation and performance standards 
for arterial prostheses" 
To the Editors: 
The report by Abbott et al. (J VASC SURG 1993;17: 
746-56) was excellent in that many investigators in the past 
have failed to classify implanted arterial conduits, including 
those intended for the coronary artery position, in a 
systematic manner. The report brings to mind some 
important concerns about the realities of testing small- 
caliber vascular grafts intended for coronary artery bypass. 
We would feel more confident about clinical applica- 
tion of synthetic oronary artery bypass conduits if they had 
been evaluated in the coronary artery position in experi- 
mental animals, rather than in some peripheral arterial 
position. We believe that a graft that is developed for use 
in the coronary artery position should not be used clinically 
before undergoing stringent esting and before its safety 
and efficacy are adequately demonstrated. Excellent pa- 
tency of straight arterial grafts in peripheral arterial sites in 
experimental nimals does not assure acceptable patency in 
the coronary artery position or the same endothelialization 
or degenerative changes because hemodynamics, graft 
flow, loaded kink, anastomotic conditions, and the overall 
environment are different between the coronary and 
peripheral arterial ocations. 
In Welz's canine study, dialdehyde starch-tanned bo- 
vine internal mammary artery grafts were implanted in the 
femoral artery position, and the grafts were dilated less than 
10% at 6 months. However, in another canine study, a 
bovine internal mammary artery graft was angiographically 
dilated with wall irregularity at 6 months in the coronary 
position) Furthermore, occurrence of thromboembolism 
after graft implantation can be difficult to detect in canine 
peripheral arteries, because collateral circulation develops 
quickly, and leg ulceration and neurologic deficits are rarely 
observed. The dislodgment of luminal thrombi from dial- 
dehyde starch-treated grafts seemed to be the cause of 
multiple embolic episodes in Curler's clinical study and was 
also noticed in the previously cited canine experiment as a 
plugged thrombus in the coronary artery position) 
Thromboembolic ncidents were not noticed in either the 
thoracic aorta or femoral artery positions. However, in 
other canine studies, it is possible that luminal thrombi do 
not form in straight grafts under high flow conditions but 
might occur in curved grafts under low-flow conditions. 
Testing of grafts in the anatomic position where they will 
ultimately be applied clinically, especially in the coronary 
artery position, should be considered, even though differ- 
ences exist between human beings with atherosclerosis and 
healthy experimental nimals. 
The most widely accepted clinical graft should be the 
control in testing a new synthetic or biosynthetic graft; 
however, the structure and strength of canine autologous 
veins differ from human saphenous veins. In an earlier 
canine study, autologous jugular vein was implanted in the 
coronary artery position. The size discrepancy between 
8 mm jugular vein and the 3 mm left circumflex coronary 
artery was obvious; 73% of the animals died within 6 days 
of operation with occluded grafts. However, after 5 years, 
five surviving animals still had patent grafts; four grafts 
were dilated, and one was aneurysmal, at three times the 
original size. 2 Human arm vein has a thin wall compared 
with saphenous vein and a tendency to form aneurysms. 
Still, clinical patency rates of arm vein grafts in the coronary 
artery position have been reported by Prieto et al. as 63% 
at 15 months to 6 years; gross abnormalities were seen in 
two grafts, and 57% at 2 years had localized stenoses as 
reported by Stoney et al. Autologous canine veins seem to 
be too weak to serve as control grafts in the coronary artery 
position. 
Polytetrafluoroethylene (PTFE) grafts are not satisfac- 
tory as a control for new coronary artery bypass grafts in 
animal experiments because of unacceptably ow patency 
rates, and the Food and Drug Administration does not 
permit use of PTFE grafts in the coronary artery position. 
Nevertheless, follow-up angiography has revealed PTFE 
graft patency rates of 64% at I year, decreasing to 14% at 
45 months in human beings? The longest surviving 
coronary PTFE graft was angiographically patent at 72 
months as reported by McCullough et al. In the canine 
coronary artery position, however, the longest surviving 
PTFE graft was patent at 6 months with antiplatelet drug 
therapy; without antiplatelet drugs, they did not remain 
patent for even 1 month. 4 Even though autologous arm 
vein has a tendency for aneurysm formation, its patency was 
much better than that observed with PTFE grafts. 
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Why did the authors not recommend the use of an 
autologous arterial graft in assessing new experimental 
coronary artery bypass conduits? We submit that autolo- 
gous arterial conduits hould be used as the control graft to 
test new small-caliber vascular grafts in the coronary artery 
position. Arterial conduits, including the internal thoracic 
artery (ITA), gasttoepiploic artery, and inferior epigastric 
artery, have been used clinically in the coronary artery 
position for years, and the ITA has markedly better 
long-term patency rates than saphenous vein grafts. Both 
the ITA and femoral artery autologous grafts have been 
successfully used in the coronary artery position in recent 
short-term canine studies. In the long-term dog experiment 
by Ono et al.,S autologous femoral artery and ITA coronary 
grafts remained patent for more than 6 months. Perfor- 
mance compared with an autogenous arterial control graft 
should be considered as the standard in future experiments 
evaluating new synthetic or biosynthetic coronary bypass 
conduits. 
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Reply 
To the Editors: 
Tomizawa and Noishiki make two points about site 
and nature of the experimental evaluation of new prosthetic 
grafts. I am not sure they have fully understood the study. 
First we maintained that the site of implantation should 
most nearly mimic the site for clinical implantation as much 
as is possible. Thus we recommend and, hence, agree with 
the authors that a graft destined for the coronary position 
should be placed in the aorta to coronary position. Size is 
another important consideration that was not mentioned. 
The issue of control graft material in a comparative 
study was also addressed. The problem involves the 
question being asked. In the "Standard" we considered a 
polytetrafluoroethylene control adequate for a study of a 
graft for the infrainguinal position if the question was 
whether the test graft was equivalent to a clinically relevant 
control. If, however, the question was whether the test 
graft was better than what is available, then the gold 
standard should be used, which, in the instance described, 
is the saphenous vein. I have no disagreement with the 
author's contention that, because there is no prosthetic 
alternative for coronary artery bypass, autogenous vein 
should be the control in studies evaluating new materials 
for heart surgery. 
I invite our Japanese colleagues to carefully reread the 
important cited document to clarify the issues that concern 
them and hope that this reply clarifies any misunderstand- 
ing. I conclude that I find it hard to believe that our Food 
and Drug Administration would ever accept data leading to 
possible human trials for a new prosthesis for coronary 
artery use other than has been specified herein. 
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Changes in arterial wall compliance after 
endovascular stenting 
To the Editors: 
We read with interest he artide by Back et al. (J VASC 
SURG 1994;19:905-11) on their experimental work con- 
cerning compliance changes in a stented canine iliac artery. 
We recently reported our findings in a canine model of an 
aortobiiliac polytetrafluoroethylene bypass graft, in which 
a Wallstent (Schneider Stent Co., St Paul, Minn.) was 
deployed across one distal anastomosis n an attempt o 
control the development ofanastomotic neointimal hyper- 
plasia. ~'2 In our experiments, we measured the arterial 
diameter with a caliper before vessel handling to select an 
appropriately sized stent, and we did not encounter the 
atrophy of the tunica media experienced by Back et al. In 
their study, the diameters of the stented vessels were greater 
than those of the nonstented controls. This raises the 
question about whether oversizing of the stent and 
overdistension f the artery caused the medial atrophy. 
Finally, Back et al. reported finding a neointima of 
uniform thickness associated with the stents. They also 
observed a loss of compliance in the stented portion of the 
vessel. Hence, at the interface of the normal artery and the 
stent, a mismatch of compliance xisted. Because they did 
not encounter a significant accumulation of neointima t 
the stent-to-artery interface, is their work in fact evidence 
